A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)
To preliminarily evaluate the 6-month progression free survival (PFS) of combining tremelimumab and durvalumab in patients with advanced HCC (in combination with TACE).
Key Eligibility Criteria
Histologically or cytologically confirmed diagnosis of HCC OR histopathological confirmation of carcinoma in the setting of clinical and radiological characteristics which, together with the pathology, are highly suggestive of a diagnosis of HCC.
- Therapeutic Area
- Type of Study
- Clinical trial
- Study Status
- Professor Peter Doran
- Principal Investigator
- Austin Duffy MB BCh MRCPI, Consultant Medical Oncologist